If you had watched Singapore Exchange roll out crypto perpetual futures filings in the US and deepen ESG disclosure tools with ESGenome, it might have felt like niche product news rather than a clear investment signal. Investors who held Singapore Exchange over the past year are up 22.4%, including dividends. If that decision sat on your desk in November 2025, what exactly did you need to believe about these moves to press buy?
The easy part of this move is behind Singapore Exchange. Zero in on 200 high quality undervalued stocks for companies trading below our estimates.
The shares cost SGD16.93 at the start of the period, and investors had to decide which story about Singapore Exchange felt more realistic.
The bullish view pointed to a Fair Value of SGD18.3, a price implied by assumptions of 9.9% annual revenue growth and earnings reaching SGD836.0 million by 2028. Supporters focused on rising Asian wealth, safe haven flows into Singapore, and new products such as regulated crypto perpetual contracts and ESG or green instruments.
The more cautious narrative suggested a Fair Value of SGD15.94, based on expectations of 5.5% revenue growth and a future P/E of 26.5x. This side highlighted risks from rival Asian exchanges, private markets and decentralized finance, along with pressure on listing activity and fee margins.
Singapore Exchange pushed ahead with crypto perpetual futures filings in the US and expanded ESGenome with Gprnt, which supported the optimistic story about product breadth and ESG tools. H2 2026 results told a more nuanced tale. Revenue reached SGD823.3m and net income was SGD355.7m, while net margin slipped to 43.2%. The evidence cut both ways.
The lesson is simple. When a market operator leans on new products and higher volumes, you need to track two figures side by side: total revenue and net margin. That makes it easier to see whether diversification is adding scale or simply diluting profitability.
Singapore Exchange now trades at SGD20.32. The selected Narrative’s Fair Value sits below the current price, which suggests its authors see the valuation leaning on strong execution rather than deep pessimism about the business.
The core argument is blunt. Record activity in multi asset derivatives and FX only works for investors if it reliably converts into profit after heavier tech spend and capital recycling. A buyer today effectively has to assume that earnings growth keeps pace with those ambitions. This raises the question of how the risk of weaker equity derivatives economics affects that view.
"The main thing that has to go right is that SGX converts record revenues in multi asset derivatives, FX and revitalised cash equities into sufficient earnings growth to offset rising expenses, technology investment and capital recycling missteps. The current valuation implies SGX shares are priced for continued strong execution on multi year growth targets and dividend commitments, even though recent downgrades point to risk of earnings expectations being revised down."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
Three companies from the same screener. Open the full list of 199 financially solid companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com